- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01921699
Macrophages Effect on Chemoresistance
Impact of Macrophages on De-Novo Chemoresistance of Adenocarcinoma Cells
Macrophages are derived from monocytes recruited to the tumor site and stimulated by specific chemokines secreted by tumor cells. These tumor associated macrophages (TAMs) have been postulated as being involved in the progression of cancer.
Based on our preliminary findings and on published data we hypothesized that macrophage-induced chemoresistance (MIC) can promote survival of pancreatic carcinoma cells during chemotherapy.
The overall goal of this study is to evaluate the mechanism of MIC in an in-vitro model of Pancreatic ductal adenocarcinoma (PDA).
methods:
- The human PDA cell line Panc1 will be grown in suitable conditions.
- Macrophages will be produced by incubating mononuclear cells from the blood of healthy donors in medium with M-CSF for 7 days.
- TAMs will be generated by culturing these macrophages with tumor-culture conditioning medium (TCCM) of PDA Cells for an additional 72 hours.
- Human pancreatic cells (PANC1) will be treated with gemcitabine following exposure to macrophages CM.
- Cell proliferation will be quantified by light microscopy and by an XTT Cell Proliferation Assay Kit.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- healthy people
Exclusion Criteria:
- refusal to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: irrelevant
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
proliferation and migration of PANC1 cell line in the tested groups.
Time Frame: one day to get the blood samples, and a year after that to complete the basic research
|
the macrophages will be isolated from the blood we'll get from the healthy volunteers.
the outcome measure is related to the basic research and not clinical so there's no symptom/outcome related to the participants.
|
one day to get the blood samples, and a year after that to complete the basic research
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To determine whether direct cell-to-cell interaction or soluble factors participate in MIC.
Time Frame: a year from obtaining the blood samples
|
a year from obtaining the blood samples
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pending (Other Grant/Funding Number: National Institutes of Allery and Infectious Diseases)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.